2 edition of Guidance on the use of paclitaxel in the treatment of ovarian cancer found in the catalog.
Guidance on the use of paclitaxel in the treatment of ovarian cancer
National Institute for Clinical Excellence.
|Statement||National Institute for Clinical Excellence.|
|Series||Technology appraisal guidance -- no. 55|
|The Physical Object|
|Pagination||19 p. ;|
|Number of Pages||19|
Background. Ovarian cancer is the fifth most common cause of cancer death in women and is the most common cause of death by a gynecological tumor, which seriously threatens the health of women [1, 2].Due to the insidious onset, rapid progression, easy intraperitoneal dissemination and metastasis in the early stage, and lack of effective early diagnosis of ovarian cancer, approximately . Chemotherapy for Ovarian Cancer Hormone Therapy for Ovarian Cancer Targeted Therapy for Ovarian Cancer Common approaches Typically, treatment plans are based on the type of ovarian cancer, its stage, and any special situations.€Most women with ovarian cancer will have some type of surgery to remove the tumor.
OVARIAN CANCER TREATMENT REGIMENS (Part 1 of 2) Clinical Trials: The NCCN recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced health care team. The purpose of this study is to assess the efficacy and safety of treatment with carboplatin / paclitaxel PLUS pembrolizumab (MK) and maintenance olaparib (MK) in women with epithelial ovarian cancer (EOC), fallopian tube cancer, or primary peritoneal cancer.
PURPOSE Topotecan and paclitaxel were evaluated in a randomized, multicenter study of patients with advanced epithelial ovarian carcinoma who had progressed during or after one platinum-based regimen. PATIENTS AND METHODS Patients received either topotecan ( mg/m2) as a minute infusion daily for 5 days every 21 days (n = ) or paclitaxel ( mg/m2) infused over 3 hours every 21 days Cited by: Objectives: To compare the efficacy and toxicity of weekly paclitaxel administered for recurrent ovarian cancer between women who received weekly versus every 3 week paclitaxel during primary therapy. Methods: A multi-institutional retrospective chart review was performed encompassing patients who received weekly paclitaxel for recurrent ovarian cancer at 3 academic institutions during
Occupational profiles of selected non-manufacturing industries in Tennessee, 1973
American banking and the money supply of the future.
Architecture on my mind
Reminiscences of Lorraine Three Legs, Standing Rock Sioux Tribe of South Dakota
Guercino drawings in the Art Museum, Princeton University, March 11 through April 6, 1969.
National viands © la mode
Oversight of the Inter-American Foundation
Evaluation of child health services
health of the public in Northern Ireland
Baby & child care
On the cutting edge of technology
And now to business
Of paclitaxel and platinumbased therapy in recurrent (or resistant) ovarian cancer is not recommended, outside the context of clinical trials. It was recommended that the NICE guidance should be reviewed once full results from a further study (ICON3) were available.
Four published RCTs on the second-line use of paclitaxel (monotherapy) in the treatment of ovarian cancer were identified. However, two of these studies compared paclitaxel with unlicensed treatments, and one compared different dosing schedules of paclitaxel itself.
Paclitaxel in combination with a platinum-based therapy (cisplatin or carboplatin) should be the standard initial therapy for patients with ovarian cancer following surgery. The use of paclitaxel/platinum combination therapy in the treatment of recurrent (or resistant) ovarian cancer is recommended if the patient has not previously received this drug combination.
Paclitaxel is not recommended as second-line (or subsequent) therapy in women with ovarian cancer who have received the drug as part of their first-line treatment.
Publication history information: Published in January NICE Technology Appraisal Guidance Guidance transferred to. An audit on the treatment of ovarian cancer could be carried out to ensure that: paclitaxel is used appropriately. women with ovarian cancer participate in making the choice concerning their therapy.
chemotherapy for women with ovarian cancer is supervised by an appropriate specialist. When NICE recommends a treatment 'as an option', the NHS must make sure it is available within 3 months of this guidance being published.
This means that, if a patient has ovarian cancer and the doctor responsible for their care thinks that paclitaxel is the right treatment, it should be available for use, in line with NICE's recommendations. The results of the JGOG study provide the strongest evidence hitherto that dose-dense weekly paclitaxel is more effective than 3-weekly paclitaxel in the treatment of epithelial ovarian cancer.
Use in Cancer. Paclitaxel is approved to be used alone or with other drugs to treat: AIDS-related Kaposi sarcoma. It is used as second-line therapy. Breast cancer. It is used: In patients with node-positive disease. It is given as adjuvant therapy with doxorubicin hydrochloride-containing combination chemotherapy.
In guidance announced on May 5, the NICE said that paclitaxel in combination with a platinum therapy (cisplatin or carboplatin) should be the standard initial therapy for women with ovarian cancer following surgery. The paclitaxel/platinum combination is also recommended in the treatment of recurrent (or resistant) ovarian cancer if the patient has not previously received this combination.
Indication(s) The TC regimen (Table 1) has been studied as adjuvant therapy in ovarian cancer 1 –8 and primary treatment of relapsed platinum-sensitive ovarian cancer.
9 Current guidelines recommend TC as primary adjuvant therapy for all stages of ovarian cancer, as therapy for recurrent platinum-sensitive tumors, and as neo-adjuvant therapy for patients with bulky stage III/IV ovarian.
To date, NICE has issued guidance for the use of three chemotherapeutic agents in the treatment of ovarian cancer: paclitaxel, topotecan, and pegylated liposomal doxorubicin. NICE guidance recommends surgery and adjuvant chemotherapy with paclitaxel/platinum combination therapy or platinum therapy alone as first-line treatment for ovarian cancer.
Currently, the suggested treatment for early-stage ovarian cancer (FIGO I and II) in the US is optimal surgical staging followed by either chemotherapy or expectant management, depending on the stage and grade of the disease Patients with Stage IA or IB disease with Grade I and II tumor have a greater than 90% cure rate, and require no further postoperative treatment, while.
Guidance on the use of paclitaxel in the treatment of ovarian cancer (updated May ) NICE TA55 Either paclitaxel in combination with a platinum compound (cisplatin or carboplatin) or a platinum compound alone are alternatives for the first-line treatment of ovarian cancer (usually following surgery).
the use of paclitaxel in the treatment of ovarian cancer Issue date January Note This guidance replaces Technology Appraisal Guidance No 3 issued in May The Institute reviews each piece of guidance it issues. The review and re-appraisal of the use of paclitaxel in the treatment of ovarian cancer has resulted in a change in the.
Guidance on the use of paclitaxel in the treatment of ovarian cancer - guidance (TA55) Source: National Institute for Health and Care Excellence - NICE - 22 January Paclitaxel (Taxol) is a chemotherapy drug often used in combination with other drugs to treat cancer.
In this case, it is used alone to treat patients with ovarian cancer who cannot tolerate platinum-based drugs, when their ovarian cancer has recurred within six months.
Paclitaxel (Taxol) is. Background: Paclitaxel and carboplatin are currently used as a standard therapy for recurrent platinum-sensitive ovarian cancer. However Paclitaxel is solubilized in cremophor which is responsible for some paclitaxel associated hypersensitivity.
Abraxane is a Cremophor EL-free, albumin-bound nanoparticle paclitaxel developed to reduce the toxicities associated with Cremophor. INTRODUCTION. Treatment of recurrent platinum-resistant ovarian and peritoneal cancers represents a therapeutic challenge. The aim of this Phase III prospective study was to compare the survival benefits, objective response rate, and toxicities among patients treated by weekly paclitaxel with those who underwent three-weekly paclitaxel in recurrent platinum-resistant ovarian and.
Taxol (paclitaxel): "I had Taxol and Cisplatin for Stage 3 ovarian cancer. After 6 treatments, each 3 weeks apart, a second surgery to check for residual cancer cells, I was declared cancer free. The Taxol severely damaged my nerves in fingers and feet, but now after 16 yrs, I have no residual damage.
The carboplatin/paclitaxel doublet remains the chemotherapy backbone for the initial treatment of ovarian cancer. This two-drug regimen, with carboplatin dosed using the Calvert formula, yielded convincing noninferior outcomes when compared with the prior, more toxic, regimen of cisplatin/paclitaxel.
Clinical trials are research studies that involve people. The clinical trials on this list are for ovarian cancer. All trials on the list are supported by NCI. NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out.
Clinical trials. NICE has positively appraised guidance on use of “Paclitaxel in the treatment of ovarian cancer” (TA), published in May ; “Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy.
Methods: Study population included advanced ovarian cancer patients who were unlikely to tolerate 3 weekly paclitaxel and carboplatin and hence received weekly paclitaxel (80 mg/m 2) and carboplatin AUC-2 as data regarding the baseline characteristics, chemotherapy tolerance, completion rates, toxicity (Common Terminology Criteria for Adverse Events version ), and .